- Report
- August 2023
- 70 Pages
Spain
From €4565EUR$4,750USD£3,915GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4565EUR$4,750USD£3,915GBP
- Report
- October 2022
- 70 Pages
Africa
From €4565EUR$4,750USD£3,915GBP
- Report
- October 2019
- 125 Pages
Canada
From €4565EUR$4,750USD£3,915GBP
- Report
- March 2019
- 160 Pages
Middle East, Africa
From €4565EUR$4,750USD£3,915GBP
- Report
- October 2022
- 176 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- March 2019
- 90 Pages
Europe
From €4565EUR$4,750USD£3,915GBP
- Report
- December 2018
- 30 Pages
China
From €2115EUR$2,200USD£1,813GBP
- Report
- February 2018
- 77 Pages
Global
From €2403EUR$2,500USD£2,061GBP
- Report
- April 2023
- 85 Pages
Global
From €3500EUR$3,901USD£3,106GBP
- Report
- September 2019
Global
From €5161EUR$5,370USD£4,426GBP
Levemir is a medication used to treat endocrine and metabolic disorders, such as diabetes. It is a long-acting insulin analog, meaning it is a synthetic form of insulin that is designed to mimic the body's natural insulin production. Levemir is used to control blood sugar levels in people with type 1 and type 2 diabetes. It is typically taken once or twice daily, depending on the individual's needs. Levemir is available in both vials and pens, and is typically injected under the skin.
Levemir is a popular medication for treating endocrine and metabolic disorders, and is widely available in many countries. It is manufactured by Novo Nordisk, a Danish pharmaceutical company, and is available in both generic and branded forms. Other companies that produce Levemir include Sanofi, Eli Lilly, and Biocon. Show Less Read more